KRYS

Krystal Biotech, Inc. Common Stock

$298.10 -3.54%

Recent alerts on KRYS

All signals →

News Draft FDA guidance could be a boon for gene therapy developers

Insider trade Sale by Thomas John Charles (EVP, General Counsel)

News Quoin (QNRX) Q2 Loss Beats Estimates

News Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?

News FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up

News IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab

News Rocket Stock Down More Than 30% in Past Six Months: Here's Why

News FULC Stock Falls as Muscle Disorder Study Misses Primary Goal

News AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag

News Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion

News Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up

News Replimune (REPL) Gains on Positive Data From Melanoma Study

News Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)

News Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why

News Vir Biotechnology (VIR) Up on Positive Data From HDV Study

News Denali's (DNLI) Candidate Selected for FDA's START Pilot Program

News Bristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo

News Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal

News Novartis (NVS) Reports Positive Long-Term Data on CSU Drug

News Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study

News Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal

News Roche's (RHHBY) Inavolisib NDA Gets FDA Priority Review Tag

News Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion

News Candel (CADL) Reports Upbeat Data From Lung Cancer Study

News Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag

Get push alerts for KRYS

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS